Novacyt shares drop as France refuses to refund virus test

PARIS (Reuters) - High-flying shares in Novacyt dropped as much as 12% on Tuesday after the healthcare diagnostics firm said a French regulator had decided against approving the company's coronavirus test for reimbursement by the state. France, like other countries, is betting on mass testing for COVID-19, the respiratory illness caused by the new coronavirus, as part of its strategy to emerge safely from the pandemic.City laboratories in France that do the bulk of testing use kits that are..